Innovations in Therapeutic Use of RF Radiation

Low Power, High Efficacy: TheraBionic operates at power levels up to 1000 times lower than those emitted by cell phones, which is a major advancement considering the safety and efficacy of the treatment.

 

Unique Frequency Range: The operation in a frequency range overlapping with human audible sound is unique. This Hz frequency amplitude-modulated radiation approach is non-invasive and patient-friendly, making it a significant departure from more aggressive cancer treatments.

 

Mechanisms Beyond Heating

1. Non-Thermal Interactions: The therapeutic action of TheraBionic is attributed to non-thermal interactions at the cellular or molecular level, which is a paradigm shift from the traditional understanding of non-ionizing radiation.
2. Resonance Effects and Cellular Signaling: The treatment might involve resonance effects that disrupt cellular signaling, indicating a sophisticated interaction with cancer cells at a fundamental level.
3. Immune System Modulation: There’s potential for this technology to modulate the immune system, adding another layer of therapeutic impact.

Broader Implications for EMF Use

1. Re-evaluating Non-Ionizing Radiation: This technology challenges the traditional view of non-ionizing radiation as biologically inert except for heating effects, suggesting a more nuanced understanding of electromagnetic fields (EMFs) and their biological interactions.
2. Balancing Benefits and Risks: The revelations about EMFs being both beneficial and potentially harmful underscore the need for a balanced approach in medical and technological applications.
3. Innovative Therapeutic Strategies: TheraBionic’s success opens doors to exploring other non-invasive treatments using EMFs, potentially revolutionizing how certain diseases are treated.
4. Safety in Technology Use: As wireless technologies become more prevalent, ensuring their safe use in daily life becomes crucial. This entails continuous research and regulation to understand and mitigate any potential risks associated with EMFs.

TheraBionic’s approach not only represents a major advancement in treating inoperable liver cancer but also serves as a catalyst for further research into the therapeutic potential of EMFs. Its development aligns with the broader goal of advancing healthcare and public health in an era increasingly influenced by wireless technologies, emphasizing the importance of continued research and innovation in this field.

Company Founded by Dr. Costa:

Dr. Costa founded a company in the U.S. named Autem. This company was alleged by TheraBionic to exploit the information and technology that Dr. Costa had obtained during his relationship with TheraBionic.

Patent Application Filed by Dr. Costa: Dr. Costa filed a U.S. patent application on April 28, 2015, titled “Hemodynamic parameter monitoring system for diagnosis of a health condition of a patient.” In this application, he named himself as the inventor. This patent application is referred to in the court documents as the “377 Application.” TheraBionic claimed that this application was developed using information and data collected by Dr. Costa using the TheraBionic P1 device and TheraBionic’s proprietary methods and procedures.

Additionally, in December 2017, Dr. Costa filed another patent application with the World International Property Organization (WIPO), referred to as the “825 Application.” This application was also a point of contention as TheraBionic alleged it required the use of their proprietary technology and information.

Background

• Timeframe: The events in this case span several years and involve activities in multiple countries.
• Technology Development: From 2001 to 2007, Drs. Boris Pasche and Alexandre Barbault developed devices transmitting electromagnetic fields at specific frequencies to treat cancer patients. This technology led to the foundation of TheraBionic in 2007, aimed at commercializing this cancer treatment technology.

Parties Involved

1. TheraBionic, Inc.: A company founded by Drs. Pasche and Barbault to commercialize their proprietary cancer treatment technology.
2. Dr. Frederico Perego Costa: A Brazilian oncologist who played a pivotal role in developing TheraBionic’s technology. He tested the OncoBionic P1 device on his patients in Brazil.

Key Issues

1. Non-Disclosure Agreement (NDA): Dr. Costa and TheraBionic were bound by an NDA starting from 2003, renewed in 2007, and again in 2012, aimed at protecting confidential information and the proprietary nature of the technology.
2. Alleged Breach of Contract: TheraBionic accuses Dr. Costa of breaching the 2012 NDA by using its confidential information and technology in his patent applications and forming his own company, Autem, to exploit this information.
3. Patent Applications and Intellectual Property: Dr. Costa filed patent applications in the U.S. and with the World International Property Organization, which TheraBionic claims were developed using their proprietary technology and information.
4. Jurisdiction and Legal Disputes: The case involves complex legal disputes over jurisdiction, personal jurisdiction, and the breach of contract claims, with Dr. Costa seeking dismissal on various grounds, including forum non conveniens (arguing the case should be adjudicated in Brazil).

Legal Proceedings

• Jurisdictional Consent: Despite Dr. Costa’s motion to dismiss the case on various grounds, the court denied these motions. The court emphasized the contractual consent Dr. Costa had given to this court’s jurisdiction and the choice of the forum as per the NDA.
• Claims Against Dr. Costa: TheraBionic’s amended complaint includes breach of contract, misappropriation of trade secrets, violation of the Defend Trade Secrets Act, and demands for injunction, conversion, replevin, and specific performance.

The court’s decision was to deny Dr. Costa’s motions to dismiss, thereby allowing TheraBionic’s claims to proceed. The case highlights the complexities involved in international contracts, intellectual property, and the enforceability of forum selection clauses in NDAs.